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Abstract
Introduction: Although postoperative delirium (POD) is a common in-hospital complication associated with negative outcomes,
evidence in liver transplantation (LT) is scarce. Objective: We examined the incidence and duration of POD, its impact on
outcomes and health-care utilization, and described predisposing and precipitating factors favoring POD development. Design:
This prospective cohort study included adults undergoing transplantation in a tertiary hospital. Postoperative delirium was
assessed 3 times daily until 24 days post-LT, with the Intensive Care Delirium Screening Checklist on the intensive care unit (ICU)
and the Delirium Observation Screening Scale on the ward. Postoperative delirium was noted if any of the daily measurements
was positive. Results: Forty-two patients (69% male, mean age 55 years, median Model for End-Stage Liver Disease score 15
[interquartile range 8-26]) were included. The incidence of POD was 45.2%, with a median duration of 5 days. Patients with POD
had longer ICU (median 8 vs 2 days, P ¼ .000) and hospital stays (median 32 vs 14 days, P ¼ .000) as well as shorter survival
(Breslow test P ¼ .045, log-rank test P ¼ .150). Pre-LT comorbidities and perioperative factors might be related to POD
development. Conclusion: Nurses are key persons in the detection of POD in the daily clinical routine. The high incidence of
POD and its negative association with patient outcomes highlight not only the relevance of systematic assessment of POD after LT
but also the need for preventive interventions.
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Introduction
Postoperative delirium (POD), a common in-hospital compli-
cation, is associated with negative outcomes, for example, mor-
tality, increased length of stay, and functional decline.1
Severely ill patients are at higher risk of developing POD and
the incidence ranges from 19% to 82%.1 Considering that organ
allocation follows the Model for End-Stage Liver Disease
(MELD), patients receiving liver transplantation (LT) are typi-
cally severely ill at the time of transplantation. Since the imple-
mentation of MELD, patients have had increased morbidity
following LT.2 Therefore, prevention of additional complica-
tion such as POD is crucial. While predisposing and precipitat-
ing risk factors contribute independently to POD’s
development, their interaction can also aggravate its progress.3
Indicating a patient’s baseline vulnerability, predisposing fac-
tors include, for example, older age, alcohol misuse, and
comorbidities such as depression.1 Precipitating factors occur
after hospital admission and include, for example, surgery,
polypharmacy, and physical restraints.1
Delirium is defined as a change in cognition, along with
disturbances of attention and awareness, characterized by
reduced capacity to direct, focus, sustain, or shift attention as
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well as reduced orientation to the environment.4 However, its
tendencies to develop quickly and fluctuate in severity over the
course of a day handicap observation-based recognition.4
Nurses are major providers of bedside care and take a leading
role in the detection of delirium. They may use a broad variety
of valid and reliable instruments to assess delirium,5 which also
precludes the risk of underrecognition of delirium as clinical
diagnosis.1,6 About 30% to 40% of delirium episodes are pre-
ventable with (non) pharmacological interventions, which
highlights the importance of monitoring the development of
POD by using assessment tools.1
The few researchers who examined POD in the LT popula-
tion have reported incidences ranging from 9.8% to 47.4%.7-13
However, the majority assessed delirium only as one of a clus-
ter of neurological complications. Examining POD as a pri-
mary post-LT outcome, though,7,12 2 recent studies
associated it with increased in-hospital and 1-year mortality,
increased length of intensive care unit (ICU) and hospital stays,
longer duration of mechanical ventilation, and higher rates of
infection or sepsis.7,12 However, both studies used retrospec-
tive designs and focused on the occurrence of POD in the ICU
without further assessment on the ward. Follow-up time was
unclear12 or limited to 1-year posttransplantation.7 Wang et al
used a validated instrument to assess POD and identified a
history of alcohol abuse, preoperative hepatic encephalopa-
thy, prolonged endotracheal intubation, and an Acute Physiol-
ogy and Chronic Health Evaluation II score 16 as risk
factors for the development of POD.12 As they included only
living-donor LT recipients, its evidence is not generalizable
across the entire LT population. To date, no prospective stud-
ies have used validated assessment instruments to measure
POD in a representative group of LT recipients. Therefore,
the aims of this study were (1) to examine the incidence and
duration of POD in LT recipients during their hospital stay,
(2) to examine the impact of POD on clinical outcomes
(ie, survival and postoperative complications) and health-
care utilization (ie, ICU and hospital length of stay), and (3)
to describe potential predisposing and precipitating factors
potentially favoring the development of POD.
Methods
Design, Setting, and Population
This prospective cohort study was conducted in the ICU for
visceral and transplant surgery and the transplant ward of the
University Hospital Zurich, where about 50 LTs per year are
conducted.14 All German-speaking adults (>18 years) awaiting
single-organ LT and competent to provide informed consent
were eligible. The primary investigator contacted all patients
on the waiting-list. Those eligible and interested received oral
and written study information. Written informed consent prior
to transplantation was mandatory before inclusion. Recruit-
ment began in December 2011; data collection lasted from
February 2012 (first participant admitted for LT) until June
2014 (end of study period). In-hospital follow-up lasted until
maximum 24 days post-LT, earlier discharge, or death. The
primary investigator collected data from patients’ medical files
and randomly error checked 10% of the entered data with a
research assistant. Data were kept confidential, with access
restricted to members of the research team. The study was
approved by the Cantonal Ethics Committee of Zurich (KEK-
ZH-Nr. 2011-0317).
Data Collection
Demographic and clinical data including recipient and donor
ages, gender, nationality, marital status, mode of hospital
admission, etiology of end-stage liver disease, first or re-LT,
type of donation, and cold ischemia time were collected from
the patients’ medical files.
Measurement of POD
In the ICU, POD was assessed with the German version of the
8-item Intensive Care Delirium Screening Checklist.15,16 This
tool is validated to screen delirium in critically ill patients by
systematic observation. Each item is rated as no (0 points), yes
(1 point), or not assessable (no scoring) and summed to a max-
imum score of 8, with scores 4 indicating delirium. As the
Intensive Care Delirium Screening Checklist is only applicable
to patients who are awake and respond to stimulation, con-
sciousness in critically ill patients must first be screened using
the Richmond Agitation Sedation Scale.17 Each patient’s level
of agitation is scored on a 10-point scale (range: 5 to þ4). As
patients with scores of 5 or 4 are deeply sedated or unar-
ousable, only patients scoring between 3 and þ4 are eligible
for POD assessment.
During the postoperative follow-up period, patients on the
ward were screened using the 13-item Delirium Observation
Screening Scale, which enables nurses to detect early signs of
delirium observable during regular care.18,19 All items are rated
as sometimes/always (1 point), never (0 point), or don’t know
(no scoring) and summed for a final score. A score3 indicates
delirium.
The systematic delirium assessment was incorporated into
the clinical routines in January 2012 in the context of the hos-
pital’s Delir-Path project, a multiprofessional practice
development and health service research project. The multi-
component delirium management protocol includes delirium
screening as well as measures to prevent and treat delirium in
acute care patients. All nurses and physicians received training
to apply the assessment instruments (M. Schubert PhD and R.
Spirig PhD Delir-Path: Detect Evaluate Control Inpatient Risk
factors, Prevent and Treat Hospital Acquired Deliriums
(Health Services Research Project). University Hospital Zur-
ich. Unpublished; 2013:1-22.). In both settings, starting on the
first full day post-LT and continuing to a maximum of 24 days
post-LT, bedside nurses screened patients in each of the 3
shifts/d for POD, documenting the results in the medical files.
As differentiation between POD and effects of anesthesia can
be problematic, patients were not assessed for POD on the day
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of surgery. For our study, the presence of POD on that day was
defined if any of the 3 daily measurements indicated delirium.
Patient Outcomes and Health-Care Utilization
Patient survival time was defined as time from LT to death or
the end of study period (June 2014). Length of ICU stay was
measured starting the first full day after surgery until discharge
to the ward or death (if it occurred in the ICU). Length of
hospital stay was measured from the first full day posttrans-
plant until discharge from hospital or death (if death occurred
before discharge). Postoperative complications were defined
according to the Classification of Surgical Complications20 and
pooled into 4 categories: mild (grades I and II), moderate
(grade III), severe (grade IV), and death (grade V). If more
than one complication occurred, the highest category men-
tioned in the medical files was noted.
Predisposing and Precipitating Factors
Factors were categorized according to Inouye and Charpen-
tier’s model of delirium etiology.3 The selection of specific
factors was based on the literature, practicability, and clinical
relevance to LT recipients (Table 1). Data were prospectively
collected from the medical files.
Data Analysis
Descriptive statistics (frequency, percentage, mean, standard
deviation [SD], median, and interquartile ranges [IQR]) were
calculated as appropriate based on measurement levels and data
distributions. The cohort was divided into 2 groups defined by
the presence or absence of POD at any time. To examine
POD’s impact on clinical outcomes and to compare potential
predisposing and precipitating factors, intergroup comparisons
were performed via Fisher exact test for categorical variables
and via the Mann-Whitney U test for continuous variables. To
explore the impact of POD on patient survival, Kaplan-Meier
analysis was performed for death, censored after follow-up
completion. Differences in survival between patients with and
without POD were examined with the Log-Rank test and the
Wilcoxon-Breslow test, which is more sensitive to earlier
events.21 A 2-tailed P value <.05 was considered statistically
significant. Statistical analysis was performed using SPSS for
Mac, release version 21 (IBM SPSS Inc, Armonk, New York).
Results
Sample Characteristics
During the study period, 197 patients were registered on the LT
waiting-list, whereof 122 could be checked up on the inclusion
Table 1. Overview of Predisposing and Precipitating Factors Potentially Favoring the Development of POD After LT.
Variables Definition Time of Data Collection
Predisposing factors
before LT
Recipient age In years at the time of LT Once
MELD Calculated MELD score (range 6-40) at the time of LT as
mentioned in the medical files
Once
Comorbidities Pre-LT comorbidities (presence or absence) as mentioned in the
medical files: Diabetes mellitus, history of depression, or need
of renal replacement therapy (hemodialysis or hemofiltration)
Once
Alcohol or tobacco Pre-LT alcohol or tobacco use (presence or absence) as
mentioned in the medical files
Once
Laboratory variables Test results from the most recent blood withdrawal before LT:
total bilirubin, sodium, alanine aminotransferase, aspartate
aminotransferase
Once
Precipitating factors at
the time of LT or
afterward
Intraoperative
hypotension
Systolic blood pressure <90 mmHg at any time during surgery
(presence or absence) as mentioned in the medical files
Once
Duration of surgery Duration of the LT surgery (in minutes) as mentioned in the
medical files
Once
Mechanical ventilation
time
Time from intubation in the operating room until extubation in
the operating room or the ICU (in minutes) as mentioned in
the medical files
Once
Renal replacement
therapy
Hemodialysis or hemofiltration after LT (presence or absence) as
mentioned in the medical files
Once
Blood transfusion Median amount of red blood cell transfusions (in liter) from
beginning of surgery until the end of in-hospital follow-up
Daily, until maximum of
24th day after LT
Medication Mean amount (in mcg or mg) of the applied medication per
patient after LT: opioid (fentanyl, morphine); sedative
(propofol, midazolam); immunosuppressive agent
(solumedrol,a prednisone, tacrolimus, cyclosporine,
mycophenolate mofetil)
Daily, until maximum of
24th day after LT
Abbreviations: MELD, Model for End-Stage Liver Disease; LT, liver transplantation; ICU, intensive care unit; POD, postoperative delirium.
aIn order to calculate the total cumulative dose of prednisone, intravenous solumedrol was converted to prednisone equivalents (1 mg solumedrol ¼ 1.25 mg
prednisone).
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criteria. Of the 98 patients who were enrolled in this study, 45
were excluded from the waiting-list due to progression of the
underlying disease or death before LT, 11 were still on the
waiting-list at the end of the study, while 42 finally received
transplants (flowchart Figure 1). The cohort was followed for a
median duration of 531 days (range 30-840 days). The sample
was predominantly male (n ¼ 29, 69%) and Swiss (n ¼ 30,
71.4%), with a mean age of 55 (SD ¼ 10.9 years). At LT, the
median calculated MELD score was 15 (IQR 8-26), and the
most common end-stage liver disease was hepatocellular car-
cinoma (n ¼ 17, 40.5%). Most patients were admitted to hos-
pital from home (n ¼ 29, 69%). Four (9.5%) organs were
derived from living donors. Our analyses revealed no relation-
ships between sample characteristics and the presence or
absence of POD (Table 2).
Incidence and Duration of POD
Nineteen (45.2%) participants developed POD while hospita-
lized, with a median duration of 5 days (IQR 2-9). Delirium
occurred mostly during the ICU stay (n ¼ 18, 95%) and within
the first 5 days post-LT. Two patients were discharged from the
ICU to the ward with ongoing POD, which disappeared within
1 day of transition. Only one developed POD on the ward. As a
quality indicator, we checked the performance of the newly
implemented POD assessment. Nurses’ full adherence to the
delirium guidelines (ie, POD assessment of each included
patient three times daily) would have resulted in 2164 POD
assessments. In practice, POD was assessed 1643 times
(75.9%).
Clinical Outcomes and Health-Care Utilization
Ten (23.8%) patients died within the follow-up time, whereof 6
(60%) had experienced POD during hospital stay. Patients with
POD had a shorter mean survival time than those who had not
(585 days [SD ¼ 80.3] vs 742 days [SD ¼ 53.6]), which was
significant with the Breslow test (P¼ .046). The Log-Rank test
yielded no significant results (P ¼ .150; Figure 2). Results for
clinical patient outcomes and health-care utilization are pre-
sented in Table 3.
Factors Potentially Favoring the Development of POD
We noted several statistically significant precipitating factors
potentially favoring POD. However, due to our small sample
size, we also paid attention to the clinically meaningful differ-
ences observed in the predisposing factors (Table 4). Compared
to patients who experienced no delirium, patients with POD
had a higher MELD score, a higher prevalence of pre-LT dia-
betes mellitus and depression, an increased need for renal
replacement therapy before and after LT, longer duration of
mechanical ventilation, longer surgery duration, more blood
transfusions, and higher volumes of administered opioids and
sedatives but less immunosuppressive medication (except
cyclosporine).
Discussion
To our knowledge, this is the first prospective cohort study to
examine POD as a primary outcome in LT recipients using
validated assessment instruments. Our results are based on
POD assessment performed by bedside nurses under normal
working conditions on the ICU and the ward. Nearly half of
the sample experienced POD during their hospital stay, mainly
in the ICU. Postoperative delirium was associated with
increased health-care utilization and decreased survival time.
Our analyses also indicated potential factors favoring POD
development.
Incidence and Duration of POD
This study group’s high incidence of POD in LT recipients is
consistent with Wang et al’s finding of 47.4% via a validated
assessment instrument.12 Studies not using validated tools
found lower rates from 9.8% to 26.7%.7-11,13 Considering delir-
ium’s characteristic fluctuations, a systematic assessment
yields greater sensitivity, and ICU nurses and physicians
underestimate the presence of delirium without using diagnos-
tic instruments.22 Consistent with previous reports, highest
POD incidence occurred early after LT.7,12 Our study’s POD
duration is comparable to previous results with a mean of
Patients lost during the waiting list period (n=45) 
• Died (n=17) 
• Delisting due to better or worse condition (n=28) 
Patients Excluded (n=24) 
• Not meeting inclusion criteria (n=20)  
• Refused to participate (n=4)  
Patients transplanted in the time from February 2012 
to June 2014 and included in analysis 
(n=42) 
Patients with informed consent but not transplanted 
during study period (n=11) 
 Eligible patients on the 
waiting list (n=122) 
Patients with informed 
consent (n=53) 
Patients Excluded (n=75) 
• No eligibility assessment possible before liver 
transplantation (i.e., organizational reasons, time 
constraints, high urgent transplant) or the end of 
the study (n=68) 
• No informed consent due to mechanical 
ventilation before liver transplantation (n=7)
Patients with informed 
consent (n=98) 
Patients on the waiting list since the beginning of recruitment on December 19th 2011 
(n=197) 
Figure 1. Flowchart of the recruitment, inclusion, and exclusion of
patients during the study period.
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5 days (SD ¼ 2.6).12 Longer POD duration accompany serious
risks: Alongside increased long-term functional decline and
cognitive disorders, even a median POD duration of 1 to 3 days
was associated with elevated 1-year mortality.23,24 In a sample
of older ICU patients, Pisani et al concluded, ‘‘each day of
delirium in the ICU increases the hazard of mortality by
10%.’’24(p1095)
Clinical Patient Outcomes
Patients with POD had a decreased survival time compared to
those without, which corroborates previous research. In a mul-
tivariate model adjusted for MELD scores, LT recipients with
POD during ICU stay had a 4-fold higher risk of dying in
hospital and a nearly 3-fold higher 1-year mortality.7 Our sur-
vival analysis showed that all 6 patients with POD during hos-
pital stay died within the first year after LT, while 3 of 4
patients without POD died later than 1 year after LT. This also
explains the significant difference in mean survival indicated
by the Breslow test, which emphasizes earlier events. Concur-
ring with previous findings, POD was also associated with
increased health-care utilization.7,12 Prolonged hospitalization
correlates with worse patient outcomes such as depression,
reduced quality of life, and higher costs.25,26 Survival and
health-care utilization are also influenced by other factors than
POD though. For example, more than 50% of our recipients
with POD also required post-LT renal replacement therapy,
which has been associated with an increased length of stay and
inferior patient and graft survival.27 Interestingly, although 11
(57.9%) of the 19 patients with POD had severe complications
or died during their hospital stay, we found no significant dif-
ferences regarding postoperative complications.
Factors Potentially Fostering POD Development
We identified several clinical and statistical differences
between patients with or without POD. We assume that
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Figure 2. Kaplan-Meier survival curves of patients with and without
POD. Patients were censored for not having experienced the event
(death) at the end of study follow-up. The Wilcoxon-Breslow test is
more sensitive to earlier events compared to the log-rank test. POD
indicates postoperative delirium.
Table 2. Demographic and Clinical Patient Characteristics.
Variables Total group (N ¼ 42) With POD (n ¼ 19) Without POD (n ¼ 23) P Value
Recipient age, mean (SD) 55 (10.9) 54 (12.0) 56 (10.2) .54
Male gender, n (%) 29 (69) 12 (63.2) 17 (73.9) .52
Swiss nationality, n (%) 30 (71.4) 15 (78.9) 15 (65.2) .50
Married/cohabitating, n (%) 35 (83.3) 16 (84.2) 19 (82.6) >.99
MELD score, median (IQR) 15 (8-26) 20 (9-30) 12 (7-21) .17
Hospital admission from home, n (%) 29 (69) 13 (68.4) 16 (69.6) >.99
Etiology of liver disease, n (%) .43
Hepatocellular carcinoma 17 (40.5) 7 (36.8) 10 (43.5)
Viral hepatitis 7 (16.6) 5 (26.3) 2 (8.7)
Alcoholic liver cirrhosis 4 (9.5) 1 (5.3) 3 (13.0)
Othera 14 (33.3) 6 (31.6) 8 (34.8)
Re-LT, n (%) 1 (2.4) 1 (5.3) 0 (0) .45
Type of donation .30
Living, n (%) 4 (9.5) 3 (15.8) 1 (4.3)
DBD, n (%) 33 (78.6) 15 (78.9) 18 (78.3)
DCD, n (%) 5 (11.9) 1 (5.3) 4 (17.4)
Cold ischemia time in minutes, median (IQR) 401 (320-461) 372 (277-486) 408 (350-453) .39
Donor age, mean (SD) 54 (17.7) 48 (21.4) 60 (12.1) .07
Abbreviations: POD, postoperative delirium; MELD, Model for End-Stage Liver Disease; LT, liver transplantation; SD, standard deviation; IQR, interquartile range;
DBD, donation after brain death; DCD, donation after cardiac death.
aFor example, Wilson disease, toxic cirrhosis, primary biliary cirrhosis, glycogenosis, and nonalcoholic steatohepatitis
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predominantly pre-LT comorbidities and early intra- and post-
operative factors might influence POD development. Comor-
bidities such as diabetes mellitus or depression have been
associated with increased risk of POD after cardiac and hip
fracture surgery.28,29 These comorbidities were also more pre-
valent in our patients with POD compared to those without. Our
finding regarding the higher need for pre-LT renal replacement
therapy in patients with POD is also supported by previous
research.7 Notably, our patients with POD also showed a sig-
nificantly increased need for post-LT renal replacement
therapy, which has not yet been studied as a POD risk factor.
Increased illness severity in our patients with POD was
reflected in their higher MELD compared to those without
POD. Although nonsignificant, this supports previous
research.9,12 In contrast, Lescot et al7 reported the same MELD
score in their patients with or without POD.
The clinical perspective suggests that some precipitating
variables not only influence the development of POD per se
but are also interrelated, as for example, longer surgery might
require greater volumes of transfused blood. While 2 studies in
Table 4. Predisposing and Precipitating Risk Factors in Patients With and Without POD.
Total Group (N ¼ 42) With POD (n ¼ 19) Without POD (n ¼ 23) P Value
Predisposing variables
Recipient age, mean (SD) 55 (10.9) 54 (12.0) 56 (10.2) .535
MELD score, median (IQR) 15 (8-26) 20 (9-30) 12 (7-21) .168
Diabetes mellitus, n (%) 9 (21.4) 5 (26.3) 4 (17.4) .707
History of depression, n (%) 10 (23.8) 6 (31.6) 4 (17.4) .468
Pre-Tx renal replacement therapy, n (%) 5 (11.9) 3 (15.8) 2 (8.7) .644
History of alcohol use, n (%) 16 (38.1) 8 (42.1) 8 (34.8) .753
History of tobacco use, n (%) 27 (64.3) 13 (68.4) 14 (60.9) .750
Total bilirubin, mmol/L, median (IQR) 25 (9-142) 32 (13-151) 16 (7-139) .312
Sodium, mmol/L, median (IQR) 138 (134-141) 138 (134-141) 139 (134-141) .416
Alanine aminotransferase, U/L, median (IQR) 43 (28-76) 36 (29-64) 48 (23-82) .879
Aspartate aminotransferase, U/L, median (IQR) 55 (38-136) 55 (40-82) 63 (31-141) .737
Precipitating variables
Systolic blood pressure <90 mmHg, n (%) 29 (69.0) 11 (57.9) 18 (78.3) .192
Surgery duration, minutes, median (IQR) 378 (310-507) 445 (386-575) 330 (290-430) .010
Mechanical ventilation, minutes, median (IQR) 1090 (699-3010) 2120 (1090-7565) 810 (615-1225) .001
Post-Tx renal replacement therapy, n (%) 14 (33.3) 10 (52.6) 4 (17.4) .023
Blood transfusion, L , median (IQR) 3.0 (1.2-5.3) 4.8 (3.0-8.4) 1.8 (0.6-3.0) .001
Fentanyl, mg, mean (SD) 166 (374.5) 334 (508.8) 27 (71.0) .002
Morphine, mg, mean (SD) 2.1 (2.7) 2.5 (2.7) 1.8 (2.6) .244
Propofol, mg, mean (SD) 119 (251.9) 256 (328.5) 6.0 (15.4) .000
Midazolam, mg, mean (SD) 0.5 (2.2) 1.0 (3.1) 0.1 (0.6) .005
Prednisone, mg, mean (SD) 64 (23.0) 56 (14.4) 71 (26.8) .019
Tacrolimus, mg, mean (SD) 4.0 (3.4) 2.8 (2.4) 5.0 (3.9) .042
Cyclosporine, mg, mean (SD) 6.7 (35.4) 11.7 (51.1) 2.6 (12.6) .864
Mycophenolate mofetil, mg, mean (SD) 566 (600.8) 499 (525.2) 621 (663.3) .746
Abbreviations: POD, postoperative delirium; MELD, Model of End-Stage Liver Disease; LT, liver transplantation; SD, standard deviation; IQR, interquartile range.
Table 3. Comparison of Clinical Patient Outcomes and Health-Care Utilization Between Patients With and Without POD.
Variable Total Group (N ¼ 42) With POD (n ¼ 19) Without POD (n ¼ 23) P Value
Postoperative in-hospital complications, n (%)
Mild (grade I and II)a 11 (26.2) 3 (15.8) 8 (34.8) .29
Moderate (grade III)b 6 (14.3) 3 (15.8) 3 (13.0) >.99
Severe (grade IV)c 12 (28.6) 8 (42.1) 4 (17.4) .10
Death (grade V) 3 (7.1) 3 (15.8) 0 (0) .08
Mortality during study period, n (%) 10 (23.8) 6 (31.6) 4 (17.4) .47
Length of stay in the ICU in days, median (IQR) 3.5 (2-7) 8 (4-23) 2 (1-3) <.000
Length of stay in hospital in days, median (IQR) 18 (13-32) 32 (19-54) 14 (11-18) <.000
Abbreviations: POD, postoperative delirium; ICU, intensive care unit; IQR, interquartile range.
aFor example, any deviation from the normal postoperative course with or without the need for pharmacological treatment, blood transfusion, total parenteral
nutrition.
bFor example, requiring surgical, endoscopic, or radiological intervention with or without general anesthesia
cFor example, life-threatening complication, single or multiorgan dysfunction.
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LT found no significant results concerning surgery duration,7,12
we noted significant longer surgery in patients with POD,
which may have entailed increased blood transfusion—a
known POD risk factor.7 Additionally, an extended mechanical
ventilation requires increased dosage of sedative medication.
Being intubated 5 days increased the risk of developing POD
nearly 2-fold,12 while benzodiazepines additionally contribute
to the risk of delirium.30 Our patients with POD also had longer
intubation time and received more sedative medication. How-
ever, sedatives are commonly administered during mechanical
ventilation in the ICU and also prescribed to treat agitated,
delirious patients. Therefore, firm conclusions concerning the
relationship between medication and POD development should
consider the time of administration, which fell beyond the
scope of our research.
Other suspected precipitating factors were post-LT immu-
nosuppressives. A common medication is tacrolimus. Although
its neurotoxicity has been described,31 neurological complica-
tions in LT recipients might be influenced by multiple fac-
tors.11 However, tacrolimus is routinely discontinued in
patients showing neurological symptoms or signs of POD. This
most likely explains why our patients with POD received less
tacrolimus than the non-POD group.
Limitations
Several limitations affected this study. First, systematic detec-
tion of POD was part of an interprofessional delirium manage-
ment program implemented 1 month before data collection
started. Although all nurses were appropriately trained to use
the instruments, a lack of experience at the beginning may have
led to POD rating errors. However, in our sensitivity analysis,
we excluded patients with <50% of the required 3 daily POD
assessments and found no changes in patient characteristics or
results regarding clinical outcomes, health-care utilization, or
mortality. Second, POD diagnoses were not physician con-
firmed. Although we used validated instruments for POD
assessment, the Intensive Care Delirium Screening Checklist’s
specificity is 57%, allowing potential false-positive ratings.
Additionally, since the Delirium Observation Screening Scale
is a screening instrument, the diagnosis of POD requires con-
firmation with the Confusion Assessment Method, which rep-
resents key elements of delirium.32 Third, the small sample size
limited the performance of multivariate statistics to determine
independent predisposing and precipitating predictors of POD.
Finally, although we carefully selected possible precipitating
and predisposing factors for our population, further factors, for
example, sleep deprivation, infections, or hepatic encephalo-
pathy, may have contributed to POD in our sample.
Clinical Implications
The high incidence and long duration of POD indicated by our
prospective and systematic assessment suggest that LT surgery
entails a particularly high POD risk. Despite the necessary
investments regarding training and administration, it is strongly
recommended to incorporate systematic POD assessment with
validated instruments into daily clinical care of LT recipients.
Additionally, as POD frequently precedes severe negative clin-
ical and economic outcomes, its relief and prevention must be
set as high-priority goals. Multicomponent (non) pharmacolo-
gical interventions can prevent or reduce the duration and
severity of POD1 and should therefore be implemented in all
centers performing LT.
Conclusion
In the current prospective study, more than 45% of LT recipi-
ents experienced POD, with a median duration of 5 days during
their hospital stay. Postoperative delirium was associated with
a 4-fold increase in ICU stay, a more than 2-fold increase in
hospital stay, and decreased survival time. Postoperative delir-
ium should not be considered as only predictive risk factor for
worse outcomes in the LT population, but as POD is a preven-
table clinical complication, our results highlight the need for
systematic assessment and the application of preventive (non)
pharmacological interventions. The identification of risk fac-
tors for POD development would be an excellent subject for
rigorous examination by future studies with larger sample
sizes. Overall, given POD’s strong associations with clinical
outcomes in LT recipients, increasing our knowledge of it will
speed the design and development of interventions targeted to
shorten its duration, and, where possible, to prevent it entirely.
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